N-(3-Methoxy-2-naphthyl)-N'-(4-methylphenyl)urea

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(3-Methoxy-2-naphthyl)-N'-(4-methylphenyl)urea
• 英文别名: 1-(3-methoxynaphthalen-2-yl)-3-(4-methylphenyl)urea
• 化学式: C₁₉H₁₈N₂O₂
• 分子量: 306.4
• InChiKey: NARZIXFXYQEUCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-(2-Methoxy-5-(trifluoromethyl)phenyl)-N'-(4-fluorophenyl)urea 、 4-氟苯胺 、 2-甲氧基-5-三氟甲基异氰酸苯酯 在 EtO 作用下， 以 乙酸乙酯 为溶剂， 反应 72.0h， 以to give the title compound as a white solid (0.60 g)的产率得到N-(3-Methoxy-2-naphthyl)-N'-(4-methylphenyl)urea
  参考文献：
  名称：

  Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas

  摘要：

  本发明涉及使用一组芳基脲类化合物治疗RAF介导的疾病，并提供用于该疗法的药物组合物。

  公开号：

  US20080269265A1

文献信息

• Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
  申请人：BAYER CORPORATION

  公开号：US20040102636A1

  公开（公告）日：2004-05-27

  This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.

  这项发明涉及使用一组芳基脲类化合物治疗细胞因子介导的疾病和蛋白酶酶介导的疾病，以及用于该疗法的药物组合物。
• INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
  申请人：Miller Scott

  公开号：US20090093526A1

  公开（公告）日：2009-04-09

  This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.

  本发明涉及使用一组芳基脲类化合物治疗细胞因子介导的疾病和蛋白酶酶介导的疾病，以及用于该疗法的制药组合物。
• Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
  申请人：Bayer Corporation

  公开号：EP1449834A2

  公开（公告）日：2004-08-25

  This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

  本发明涉及芳基脲类在治疗雷夫介导的疾病中的应用，以及用于此类治疗的药物组合物。
• Methods for promoting survival of transplanted tissues and cells
  申请人：Johnson & Johnson Vision Care, Inc.

  公开号：EP1676574A2

  公开（公告）日：2006-07-05

  Methods for enhancing the survival of a cell, tissue, or organ transplanted into a recipient comprising contacting the cell, tissue, or organ graft with an agent that decreases the rate of coagulation on the transplanted cell, tissue or organ are disclosed. The agent is one that acts by reducing the amount or activity of tissue factor (TF) on the donor tissue, such as a p38 MAPK inhibitor, a JNK inhibitor, a p38 MAPK/JNK dual inhibitor and a TF antagonist. Cells, tissues and organs treated with those agents are also disclosed.

  本发明公开了提高移植到受者体内的细胞、组织或器官存活率的方法，该方法包括使细胞、组织或器官移植体与一种能降低移植细胞、组织或器官凝血率的药剂接触。这种药剂通过减少供体组织上组织因子（TF）的数量或活性发挥作用，如 p38 MAPK 抑制剂、JNK 抑制剂、p38 MAPK/JNK 双抑制剂和 TF 拮抗剂。还公开了用这些制剂处理的细胞、组织和器官。
• Methods of promoting osteogenesis
  申请人：——

  公开号：US20040162289A1

  公开（公告）日：2004-08-19

  The invention is directed to methods of bone healing by administering a p38 MAP kinase inhibitor. The invention is directed to methods of treating bone fractures, bone diseases, bone grafting, especially enhancing bone healing following facial reconstruction, maxillary reconstruction, mandibular reconstruction or tooth extraction, enhancing long bone extension, enhancing prosthetic ingrowth, and increasing bone synostosis by administering a p38 MAP kinase inhibitor.

  本发明涉及通过施用 p38 MAP 激酶抑制剂促进骨愈合的方法。本发明涉及通过施用 p38 MAP 激酶抑制剂来治疗骨折、骨病、骨移植，特别是在面部重建、上颌骨重建、下颌骨重建或拔牙后增强骨愈合、增强长骨延伸、增强假体植入和增加骨合的方法。